Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue

Journal of Controlled Release

Volumn 52, Issue 1-2, 1998, Pages 205-213

  Rothen Weinhold, Alexandra ^a,b   Besseghir, Kamel ^c   De Zelicourt, Yves ^d   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b F 74166   (France)

^c DEBIOPHARM SA   (Switzerland)

^d 60 Rue Auber   (France)

Author keywords

Burst effect; Controlled release system; Implant; In vivo release; Poly(lactic co glycolic) acid; Polylactic acid; Vapreotide

Indexed keywords

PEPTIDE HORMONE; POLYLACTIC ACID; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

ARTICLE; BIODEGRADATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG RELEASE; GROWTH HORMONE RELEASE; HORMONE INHIBITION; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; LACTIC ACID; MALE; MOLECULAR WEIGHT; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN;

EID: 0032473541     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00216-2     Document Type: Article

References (37)

1. V. Schusdziarra, Somatostatin: biological actions and physiopathology. in: C. Scarpignato. (Ed.), Octreotide: from basic science to clinical medicine. Progress in Basic Clinical Pharmacology, Basel, 1996, pp. 35-53.
2. A.G. Harris, Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut supplement, 3 (1994) s1-s4.
3. Parmar H., Phillips R.H., Lightman S.L. Somatostatin analogues: mechanisms of action. Recent Results Cancer Res. 129:1993;1-24.
4. Lamberts S.W.J., Van der Lely A.J., De Herder W.W., Hofland L.J. Octreotide. N. Engl. J. Med. 334:1996;246-254.
5. Hofland L.J., Van Koetsveld P.M., Waaijers M., Zuyderwijk J., Lamberts S.W.J. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology. 134:1994;301-306.
6. 2 and decreases elevated prolactin levels in rats. Endocrinology. 123:1988;1735-1739.
7. Pinski J., Schally A.V., Halmos G., Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int. J. Cancer. 55:1993;963-967.
8. Siegel R.A., Langer R. Controlled release of polypeptides and other macromolecules. Pharm. Res. 1:1984;210.
9. Hall R., GomezPan A. The hypothalamic regulatory hormones and their clinical applications. Adv. Clin. Chem. 18:1976;173-212.
10. Lim L.Y., Gould P., Dickinson N.A., Collett J.H. The influence of environmental conditions on damage in L-polylactic acid during gamma irradiation. Proc. Int. Symp. Control. Rel. Bioact. Mater. 15:1988;111-112.
11. Shih C. Chain-end scission in acid catalyzed hydrolysis of poly(D,L-lactide) in solution. J. Control. Rel. 34:1995;915.
12. Heya T., Okada H., Ogawa Y., Toguchi H. Factors influencing the profiles of TRH release from copoly(D,L-lactic/glycolic acid) microspheres. Int. J. Pharm. 72:1991;199-205.
13. Asano M., Fukuzaki H., Yoshida M., Kumakura M., Mashimo T., Yuasa H., Imai K., Yamanaka H. In vivo characteristics of low molecular weight copoly(D,L-lactic acid) formulations with controlled release of LH-RH agonist. Biomaterials. 10:1989;559-573.
14. Ogawa Y., Yamamoto M., Takada S., Okada H., Shimamoto T. Controlled release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer. Chem. Pharm. Bull. 36:1988;1502-1507.
15. Niwa T., Takeuchi H., Hino T., Nohara M., Kawashima Y. Biodegradable submicron carriers for peptide drugs:preparation of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate by a novel emulsion-phase separation method in an oil system. Int. J. Pharm. 121:1995;4554.
16. Sanders L.M., Kent J.S., McRae G.I., Vickery B.H., Tice T.R., Lewis D.H. Controlled release of a luteinizing hormone-releasing hormone analogue from poly (D,L-lactide-co-glycolide) microspheres. J. Pharm. Sci. 73:1984;1294-1297.
17. Kaetsu I., Yoshida M., Asano M., Yamanaka H., Imai K., Yuasa H., Mashimo T., Suzuki K., Katakai R., Oya M. Biodegradable implant composites for local therapy. J. Control. Rel. 6:1987;249-263.
18. D. Ganderton, The development of peptide and protein pharmaceuticals. in: R.C. Hider, D. Barlow. (Eds.), Polypeptide and protein drugs: Production, characterization and formulation. Horwood, 1991, pp. 211-227.
19. A. Rothen-Weinhold, K. Besseghir, R. Gurny, Analysis of the influence of polymer characteristics and core loading on the in vivo release of a somatostatin analogue. Eur. J. Pharm. Sci. (1996) (in press).
20. J. Heller, Biodegradable polymers in controlled drug delivery. in: Therapeutic drug carrier systems. CRC Press, Boca Raton, FL, 1984.
21. Cohn D., Younes H., Marom G. Amorphous and crystalline morphologies in glycolic acid and lactic acid polymers. Polymer. 28:1987;2018-2022.
22. R. Langer, W.D. Rhine, D.S.T. Hsieh, R. Bawa, Polymers for the sustained release of macromolecules: applications and control of release kinetics. Controlled release of bioactive materials: based on the symposium at the 6th international meeting of the controlled release society in the New Orleans, 1980, pp. 83-98.
23. Eppstein D.A., Longenecker J.P. Alternative delivery systems for peptides and proteins as drugs. Crit. Rev. Ther. Drug Carrier Systems. 5:1988;99-139.
24. Engelberg I., Kohn J. Physico-mechanical properties of degradable polymers used in medical applications: a comparative study. Biomaterials. 12:1991;292-304.
25. M.C. RauxDemay, F. Girard, Facteurs de stimulation de l'axe hypothalamo hypophysosurrénalien (ACTH et peptides de la proopiomélanocortine). in: J.P. Giroud, G. Mathé, G. Meyniel. (Eds.), Pharmacologie clinique, bases de la thérapeutique. Expansion Scientifique Française, Paris, 1988, pp. 2246-2253.
26. Bergsma J.E., Rozema F.R., Bos R.R.M., Boering G., de Bruijn W.C., Pennings A.J. In vivo degradation and biocompatibility study of in vitro predegraded as polymerized polylactide particles. Biomaterials. 16:1995;267-274.
27. Bodmer D., Kissel T., Traechslin E. Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. J. Control. Rel. 21:1992;129-137.
28. Rafler G., Jobmann M. Controlled release systems of biodegradable polymers. Drugs made in Germany. 37:1994;83-88.
29. Holland S.J., Tighe B.J., Gould P.L. Polymers for biodegradable medical devices. 1. The potential of polyesters as controlled macromolecular release systems. J. Control. Rel. 4:1986;155-180.
30. Gurtler F., Kaltsatos V., Boisramé B., Gurny R. Long-acting soluble bioadhesive ophthalmic drug insert (BODI) containing gentamicin for veterinary use: optimization and clinical investigation. J. Control. Rel. 33:1995;231-236.
31. Zhang X., Wyss U.P., Pichora D., Goosen M.F.A. A mechanistic study of antibiotic release from biodegradable poly(D,L-lactide) cylinders. J. Control. Rel. 31:1994;129-144.
32. Shah S.S., Cha Y., Pitt C.G. Poly(glycolic acid-co-D,L-lactic acid): diffusion or degradation controlled drug delivery? J. Control. Rel. 18:1992;261-270.
33. Vert M., Li S., Garreau H. More about the degradation of LA/GA-derived matrices in aqueous media. J. Control. Rel. 16:1991;15-26.
34. Wise, D.L., Fellmann, T.D., Sanderson, J.E., Wentworth, R.L. Drug carriers in biology and medicine. Lactic/glycolic acid polymers. New York, Academic Press, 1979.
35. Siegel R.A., Kost J., Langer R. Mechanistic studies of macromolecular drug release from macroporous polymers. I. Experiments and preliminary theory concerning completeness of drug release. J. Control. Rel. 8:1989;223-236.
36. Weiler W., Gogolewski S. Enhancement of the mechanical properties of polylactides by solid-state extrusion I. Poly(D-lactide). Biomaterials. 17:1996;529-535.
37. J.B. Gregory, P.M. Newberne, D.L. Wise, L.C. Bartholow, J.B. Stanbury, Results on biodegradable cylindrical subdermal implants. Polym. Deliv. Syst., (1978) 121-136.